BIO vs ESPR · rev $2.58B vs rev $332.3M
BIO (BIO) versus Esperion Therapeutics Inc (ESPR) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
BIO currently screens at market cap $0. ESPR currently screens at market cap $816.9M.
Not investment advice. Open the BIO and ESPR stock pages for the full models.
Not investment advice.